Status:
UNKNOWN
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma
Lead Sponsor:
PrimeVax Immuno-Oncology Inc.
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Autologous monocyte-derived dendritic cells pulsed with tumor lysate (PV-001-DC) will be given to a group of 3 people. If this is found to be safe, it will be given to up to 7 other people, for a tota...
Eligibility Criteria
Inclusion
- Biopsy confirmed patients with un-resectable AJCC Stage III or IV melanoma who have measurable disease. Measurable disease is required, and is defined as tumor can be measured in two dimensions.
- Patient must have progressed with prior therapy with a PD-1 / PD-L1 antagonist alone or in combination with anti-CTLA-4. If the patient is positive for BRAF, the patient must have progressed on at least one BRAF inhibitor in addition to a PD-1 / PD-L1 inhibitor alone or in combination with CTLA4 for metastatic melanoma.
- Tumor specimens must be available for tumor lysates and immunological studies.
- ECOG Performance Status of ≤ 2 (corresponds to a Karnofsky Performance Status (KPS) of ≥ 70).
- Patients must be 18 years or older and able to give informed consent.
- Adequate bone marrow function of White Blood Cell (WBC) count to ≥ 1,500/uL; platelet count ≥ 100,000/mm3; absolute neutrophil count (ANC) \> 1,200/uL
- Patients must have adequate renal function by serum creatinine of ≤ 2.0 mg/dL.
- Adequate hepatic function of bilirubin ≤ 2.5 mg/dL; SGOT/SGPT \< 3× upper limit of normal (ULN).
- Patients must have the required wash out periods from prior therapy:
- Topical therapy: 2 weeks.
- Chemotherapy and radiotherapy: 4 weeks.
- Other investigational therapy: 4 weeks
- Patients of reproductive potential and their partners must agree to use an effective (\>90% reliability) form of contraception during the study and for 4 weeks following the last study drug.
- Women of reproductive potential must have a negative urine pregnancy test.
- Patients should have a life expectancy of \> 6 months.
- Patient should be able to comply with the treatment schedule and have the ability to understand and willingness to sign the informed consent document.
- Patients with manageable central nervous system metastases may be selected to this trial. The CNS metastases are defined as manageable if there is no progression for at least 4 weeks as determined by clinical examination and brain imaging (MRI and/or CT).
Exclusion
- Pre-existing autoimmune or antibody mediated disease including systemic lupus erythematous, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.
- Known history of human immunodeficiency virus (HIV) or any active immunosuppressive systemic infection or a suppressed immune system, including acquired immuno-deficiency syndrome (AIDS) or HIV positivity and known hepatitis infections (HCV or HBC), as assessed by serology.
- Patients on immunosuppressive therapy. Concurrent steroid use of not more than an equivalent of 10 mg of prednisone is allowed.
- Previous organ transplantation.
- Patients with active infection or with a fever \>101°F (38.5°C) within 3 days prior to the first scheduled treatment.
- Concurrent participation in other treatment related clinical studies. Non-treatment studies (e.g. observation or tumor cell analysis studies) are allowed.
- Prior malignancy (active within 3 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
- o Significant cardiovascular disease (i.e., New York Heart Association (NYHA) class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
- Female patients who are pregnant or lactating.
- Patients taken off Checkpoint Blockade agents: Ipilimumab, Nivolumab, Pembrolizumab, for Grade 3 or greater autoimmune toxicity.
- Patients who are positive for B-RafV600 mutation and are responding to targeted therapy.
- Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with his/her participation in the study, or to interfere with the interpretation of the results.
- Patients with endocrinopathy greater than grade III.
- Patients who have undergone a splenectomy in their previous medical history will be excluded from this trial. Evidence of a splenectomy will be from history or records.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03803397
Start Date
April 1 2024
End Date
December 31 2024
Last Update
July 6 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.